Although the development of specific IRE1α activators remains primarily at a preclinical stage, a promising cancer therapeutic approach would be to utilize small molecule IRE1α activators to induce ferroptosis selectively in tumors or to restore ferroptosis in tumors that have developed resistance to this mechanism of cell death. The gene discussed is ERN1; the disease is cancer.